MHC Class I vs MHC Class II: Key Differences and Functions
Major Histocompatibility Complex (MHC) molecules are essential for immune recognition and response. They are specialized glycoproteins that present antigens to T cells, allowing the immune system to identify and eliminate pathogens or abnormal cells. MHC molecules are classified into Class I and Class II, each with distinct structures, functions, and roles in immune defense.
This article explores the differences between MHC class I and MHC class II, highlighting their unique features and immune significance.
1. Overview of MHC Molecules
MHC molecules play a crucial role in antigen presentation, enabling the adaptive immune system to recognize infected or abnormal cells.
- MHC Class I: Found on almost all nucleated cells; presents antigens to CD8+ cytotoxic T cells.
- MHC Class II: Found on antigen-presenting cells (APCs); presents antigens to CD4+ helper T cells.
2. Key Differences Between MHC Class I and MHC Class II
Feature | MHC Class I | MHC Class II |
---|---|---|
Expression | Present on all nucleated cells. | Restricted to professional APCs (e.g., dendritic cells, macrophages, B cells). |
Antigen Source | Endogenous (intracellular antigens, e.g., viral proteins). | Exogenous (extracellular antigens, e.g., bacterial toxins). |
Associated T Cells | CD4+ helper T cells. | |
Peptide Binding Groove | Closed ends, binds peptides 8–10 amino acids long. | Open ends, binds peptides 13–25 amino acids long. |
Structure | Composed of a heavy α chain and β2-microglobulin. | Composed of α and β chains of equal size. |
Peptide Loading Site | Endoplasmic reticulum (ER). | Specialized endosomal compartments. |
Function | Kills infected or abnormal cells. | Activates immune responses and helps B cells produce antibodies. |
3. Structure of MHC Class I and Class II
MHC Class I
- Structure:
- Consists of a heavy α chain (with α1, α2, and α3 domains) and a β2-microglobulin chain.
- The α1 and α2 domains form the peptide-binding groove.
- The groove accommodates short peptides (8–10 amino acids) due to its closed ends.
- Expression:
- Found on the surface of all nucleated cells, ensuring cytotoxic T cells can recognize infected or malignant cells.
MHC Class II
- Structure:
- Composed of two chains: α chain and β chain, each with two domains (α1/β1 and α2/β2).
- The α1 and β1 domains form the peptide-binding groove.
- The groove binds longer peptides (13–25 amino acids) because it has open ends.
- Expression:
- Restricted to antigen-presenting cells (APCs), such as dendritic cells, macrophages, and B cells.
4. Antigen Processing and Presentation
MHC Class I Pathway
Step | Details |
---|---|
Antigen Source | Endogenous antigens (e.g., viral proteins or tumor antigens). |
Processing | Antigens are degraded by proteasomes into short peptides. |
Peptide Loading | Peptides are transported into the ER by TAP (Transporter Associated with Antigen Processing), where they bind to MHC class I molecules. |
Presentation | Peptide-MHC complexes are transported to the cell surface to present to CD8+ cytotoxic T cells. |
MHC Class II Pathway
Step | Details |
---|---|
Antigen Source | Exogenous antigens (e.g., bacterial toxins, extracellular pathogens). |
Processing | Antigens are taken up via phagocytosis or endocytosis and degraded in acidic endosomes. |
Peptide Loading | MHC class II molecules bind peptides in a specialized endosomal compartment after the invariant chain is removed. |
Presentation | Peptide-MHC complexes are transported to the cell surface to present to CD4+ helper T cells. |
5. Immune Functions
MHC Class I
- Activates CD8+ cytotoxic T cells, which kill infected or malignant cells by inducing apoptosis.
- Important for defending against intracellular pathogens, such as viruses.
MHC Class II
- Activates CD4+ helper T cells, which coordinate the immune response.
6. Clinical Significance
Disease/Condition | Role of MHC Molecules |
---|---|
Autoimmune Diseases | Aberrant MHC presentation can trigger autoimmune responses (e.g., Type 1 diabetes, rheumatoid arthritis). |
Transplant Rejection | MHC molecules are critical for tissue compatibility; mismatches trigger rejection. |
Cancer | Downregulation of MHC class I by tumor cells allows them to evade immune surveillance. |
Vaccines | Effective vaccines require antigens that can be presented by MHC class I or II molecules to elicit strong immune responses. |
7. Summary Table
Feature | MHC Class I | MHC Class II |
---|---|---|
Expression | All nucleated cells. | Antigen-presenting cells (APCs). |
T Cell Interaction | CD4+ helper T cells. | |
Antigen Source | Endogenous (intracellular pathogens). | Exogenous (extracellular pathogens). |
Peptide Length | 8–10 amino acids. | 13–25 amino acids. |
Function | Cytotoxic T cell activation; cell killing. | Helper T cell activation; immune coordination. |
Conclusion
MHC class I and class II molecules are indispensable components of the adaptive immune system, enabling the recognition and elimination of pathogens and abnormal cells. While MHC class I activates cytotoxic responses to intracellular threats, MHC class II orchestrates helper T cell-mediated responses to extracellular pathogens. Understanding these molecules is key to advancing immunotherapy, vaccine development, and transplant medicine.
References
- Alberts, B., et al., 2015. Molecular Biology of the Cell. 6th Edition. Garland Science.
- Janeway, C.A., et al., 2001. Immunobiology: The Immune System in Health and Disease. Garland Publishing.
- Neefjes, J., et al., 2011. MHC class I and II antigen presentation. Nature Reviews Immunology, 11(12), pp.823-836.
- Rock, K.L., et al., 2016. Pathways of antigen processing and presentation. Immunology Reviews, 272(1), pp.9-27.
- Klein, J., Sato, A., 2000. The HLA system: Genetics, immunology, clinical testing, and clinical implications. Blood, 95(8), pp.2607-2620.
Recent Posts
-
Tigatuzumab Biosimilar: Harnessing DR5 for Targeted Cancer Therapy
Tigatuzumab is a monoclonal antibody targeting death receptor 5 (DR5), a member of the …17th Dec 2025 -
Enavatuzumab Biosimilar: Advancing TWEAKR-Targeted Therapy in Cancer
Enavatuzumab is a monoclonal antibody targeting TWEAK receptor (TWEAKR, also known as …17th Dec 2025 -
Alemtuzumab Biosimilar: Advancing CD52-Targeted Therapy
Alemtuzumab is a monoclonal antibody targeting CD52, a glycoprotein highly expressed o …17th Dec 2025